News Detail

Genor Biopharma's GB251(ADC) IND application has been received by Shanghai CFDA

2017-04-14 10:53

Apr. 14, 2017 – Genor Biopharma Co., Ltd.,Shanghai, CHINA

Genor Biopharma has submitted GB251(ADC) IND application to Shanghai CFDA, and has been received the Notice of Acceptance of Drug applicationfor registration of Shanghai Food and Drug Administration Noctice Reference number: CXSL1700030沪; application matters: New drug application; Classification: Class 1; Therapeutic biological products; Declaration stage: Clinical.

For Detail, Pleasee see Walvax's (300142) Announcement2017-019

About Genor BioPharma

        Founded in 2007, Genor BioPharma Co. Ltd. is aninnovation-driven biopharmaceutical company focused on development andcommercialization of therapeutic monoclonal antibodies (mAbs) and Fc-fusionproteins. Genor has more than 10 products in the pipeline, six ofwhich are atIND and clinical stages, including GB221, GB232, GB242, GB222, GB241 and GB224.Genor has approximately 160 employees, and a well-integrated expert andmanagement team with entrenched experience and expertise from USbiopharmaceutical giants such as Amgen, Genentech, and Abbott etc. Genor hasestablished a 6,000 m2 researchand development center, which includes R&D and process development labs,analytical and quality center, and a cGMP clinical production facility. Itscommercial-scale cGMP production facility is also under planning. For moreinfo, please visit: www.genorbio.com.